[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Chen IL, Yang SN, Hsiao CC, Wu KS, Sheen JM: Treatment with high-dose methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma. Pediatr Neonatol; 2008 Aug;49(4):141-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with high-dose methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma.
  • Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome, is rapidly progressing and involves life-threatening complications that can occur in patients receiving chemotherapy and/or bone marrow transplantation.
  • We present a case of rhabdomyosarcoma ina 21-month-old boy who developed pancytopenia, dyspnea, jaundice, massive ascites and body weight gain of more than 10% after receiving conventional chemotherapy.
  • Hepatic VOD was diagnosed.
  • He recovered after supportive care and treatment with high-dose methylprednisolone.
  • [MeSH-major] Glucocorticoids / administration & dosage. Head and Neck Neoplasms / complications. Hepatic Veno-Occlusive Disease / drug therapy. Methylprednisolone / administration & dosage. Rhabdomyosarcoma / complications

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054920.001).
  • [ISSN] 1875-9572
  • [Journal-full-title] Pediatrics and neonatology
  • [ISO-abbreviation] Pediatr Neonatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


2. Cescon M, Grazi GL, Assietti R, Scanni A, Frigerio F, Sparacio F, Ercolani G, Cavallari A: Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transpl Int; 2003 Jun;16(6):437-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient.
  • Although an increased incidence of de novo malignancies is reported in transplant recipients, rhabdomyosarcoma, an aggressive mesenchymal tumor typical of childhood, is not considered a neoplasm commonly related to immunosuppression.
  • A 21-year-old woman presented with unilateral diplopia and proptosis 16 months after liver transplantation for fulminant hepatic failure.
  • A tumoral mass originating from the medial rectus muscle was partially removed and diagnosed as being an embryonal rhabdomyosarcoma.
  • Since the patient refused complete orbital excision, one course of radiotherapy and six courses of chemotherapy were administered, while immunosuppression was re-modulated, without interruption of the administration of cyclosporine.
  • Complete control of tumor growth was achieved, while no alterations of graft function were observed throughout the treatment period.
  • [MeSH-major] Liver Transplantation / adverse effects. Orbital Neoplasms / etiology. Rhabdomyosarcoma, Embryonal / etiology
  • [MeSH-minor] Adult. Female. Humans. Immunosuppression / adverse effects. Liver / physiopathology. Magnetic Resonance Imaging. Male. Reoperation. Treatment Outcome


3. Ali S, Russo MA, Margraf L: Biliary rhabdomyoscarcoma mimicking choledochal cyst. J Gastrointestin Liver Dis; 2009 Mar;18(1):95-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was jaundice, liver palpable 3 cm below right costal margin, no ascites or palpable masses.
  • CT scan showed a non-calcified heterogeneously enhancing mass centered at the liver hilum.
  • MRCP showed a large heterogeneously enhancing, partially solid mass in the region of the porta hepatic.
  • Liver biopsy revealed patternless proliferation of polymorphic oval to spindled shaped neoplastic cells.
  • Immunohistochemistry revealed positivity for vimentin, desmin.These findings were diagnostic for biliary rhabdomyosarcoma.There was no evidence of metastasis.
  • Chemotherapy was initiated.
  • Repeat imaging 6 months after initiation of treatment showed improvement in the degree of intrahepatic ductal dilatation and decrease in tumor bulk size.
  • Rhabdomyosarcoma is the most common malignant tumor of the biliary tree in childhood.
  • It is difficult to diagnose and delayed diagnosis influences the prognosis.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Choledochal Cyst / diagnosis. Rhabdomyosarcoma / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child, Preschool. Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Humans. Immunohistochemistry. Jaundice, Obstructive / etiology. Male. Predictive Value of Tests. Pruritus / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337643.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


Advertisement
4. Gilbert JA, Frederick LM, Ames MM: The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res; 2000 Nov;6(11):4365-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production.
  • In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A.
  • Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver.
  • Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues.
  • To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.
  • Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines.
  • [MeSH-major] Aromatic Amino Acid Decarboxylase Inhibitors. Carbidopa / pharmacology. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. Humans. Ileum / enzymology. Liver / enzymology. Microscopy, Electron. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 58450
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Aromatic Amino Acid Decarboxylase Inhibitors; 0 / Enzyme Inhibitors; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


5. Cecen E, Uysal KM, Ozguven A, Gunes D, Irken G, Olgun N: Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature. Pediatr Hematol Oncol; 2007 Dec;24(8):615-21
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature.
  • Although veno-occlusive disease of the liver is a well-known complication of high-dose chemotherapy and bone marrow transplantation, it has rarely been observed in children who receive conventional chemotherapy.
  • It has been very uncommon in rhabdomyosarcoma patients until recently, although they commonly receive similar anticancer agents.
  • Here the authors report a 2-year-old boy with rhabdomyosarcoma who developed veno-occlusive disease while receiving VAC (vincristine, actinomycin D, cyclophosphamide) chemotherapy regimen according to the IRS-IV protocol.
  • The patient gradually recovered during 2 weeks with supportive treatment only.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatic Veno-Occlusive Disease / chemically induced. Rhabdomyosarcoma / complications. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dactinomycin / administration & dosage. Dactinomycin / adverse effects. Humans. Male. Remission Induction. Vincristine / administration & dosage. Vincristine / adverse effects. Wilms Tumor / complications. Wilms Tumor / therapy

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092252.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  • [Number-of-references] 21
  •  go-up   go-down


6. Ishaqi MK, Jamil A, Khanani M, Baroudi M, Trad O, El-Hayek M, Bouffet E: Hepatic Sinusoidal Obstruction Syndrome in a child after chemotherapy for medulloblastoma. J Neurooncol; 2010 Mar;97(1):137-41
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic Sinusoidal Obstruction Syndrome in a child after chemotherapy for medulloblastoma.
  • Hepatic Sinusoidal Obstruction Syndrome (HSOS), the new name given to veno-occlusive disease (VOD) of the liver, is a well-known complication of high-dose chemotherapy employed with hematopoietic stem cell transplantation, but it has rarely been observed in children who receive conventional chemotherapy.
  • HSOS following standard chemotherapy has been reported in patients receiving vincristine, actinomycin D, and cyclophosphamide for the treatment of Wilms tumor and more rarely rhabdomyosarcoma.
  • We report a 14-year-old boy with high risk medulloblastoma treated with craniospinal radiation followed by chemotherapy, who experienced severe HSOS after only one course of chemotherapy including carboplatin, vincristine, and cyclophosphamide.
  • To our knowledge, this is the second report of HSOS after standard dose chemotherapy for brain tumor in childhood.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy / adverse effects. Hepatic Veno-Occlusive Disease / chemically induced. Vincristine / adverse effects
  • [MeSH-minor] Adolescent. Cerebellar Neoplasms / drug therapy. Humans. Male. Medulloblastoma / drug therapy

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):245-51 [9251728.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):993-6 [10800069.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1220-3 [9849483.001]
  • [Cites] Cell Cycle. 2007 Oct 15;6(20):2453-7 [17786054.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(9):895-7 [11781652.001]
  • [Cites] Bone Marrow Transplant. 2005 Dec;36(11):939-45 [16184181.001]
  • [Cites] Ann Intern Med. 1979 Feb;90(2):158-64 [36019.001]
  • [Cites] Pediatr Blood Cancer. 2006 Apr;46(4):521-3 [16317738.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1345-53 [18224664.001]
  • [Cites] Hepatology. 1984 Jan-Feb;4(1):116-22 [6363247.001]
  • [Cites] Eur J Pediatr Surg. 2000 Oct;10 (5):300-3 [11194540.001]
  • [Cites] Med Pediatr Oncol. 1995 May;24(5):334-40 [7700188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):477-84 [9231669.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Mar;25(3):248-51 [12621246.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 15;95(20):1548-51 [14559878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1031-7 [16343801.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):44-8 [12764742.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):208-10 [19373780.001]
  • [Cites] Pediatr Hematol Oncol. 2007 Dec;24(8):615-21 [18092252.001]
  • [Cites] Transplantation. 1987 Dec;44(6):778-83 [3321587.001]
  • [Cites] Mayo Clin Proc. 2003 May;78(5):589-98 [12744547.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):295-300 [2056973.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2435-9 [9191535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):362-72 [16168831.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2554-9 [14670928.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):222-8 [9440746.001]
  • [Cites] Folia Morphol (Warsz). 2004 Feb;63(1):91-3 [15039909.001]
  • [Cites] Arch Pathol Lab Med. 1985 Apr;109(4):367-9 [2985019.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2696-704 [11352962.001]
  • [Cites] Hepatology. 1994 May;19(5):1171-81 [8175139.001]
  • [Cites] Acta Paediatr. 2001 May;90(5):580-3 [11430722.001]
  • [Cites] Transplant Proc. 2005 Jun;37(5):2285-9 [15964400.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jan;26(1):52-5 [14707715.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1525-30 [2167951.001]
  • (PMID = 19701718.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


7. Huber J, Sovinz P, Freidl T, Jahnel J, Lackner H, Höllwarth M, Otte JB, Urban C: Long term survival in two children with rhabdomyosarcoma of the biliary tract. Klin Padiatr; 2008 Nov-Dec;220(6):378-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term survival in two children with rhabdomyosarcoma of the biliary tract.
  • BACKGROUND: Due to low incidence, rhabdomyosarcoma (RMS) of the biliary tract poses numerous complex management problems especially in diagnosis and local therapy.
  • Nearly complete tumor regression was achieved by chemotherapy and irradiation according to the CWS-protocol.
  • 4 years after diagnosis with a good quality of life.
  • CONCLUSIONS: Even in well responding biliary rhabdomyosarcomas, surgery after chemotherapy and radiotherapy seems to be necessary.
  • Adjuvant chemotherapy should be continued after hepatic lobectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Neoadjuvant Therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Survivors
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949674.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Mainguené C, Choquenet C, Cucchi JM, Dupré F, Monticelli I, Michiels JF, de Pinieux G, Vieillefond A: [Primary pleomorphic rhabdomyosarcoma of the kidney in adults: unusual tumor]. Prog Urol; 2003 Sep;13(4):679-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pleomorphic rhabdomyosarcoma of the kidney in adults: unusual tumor].
  • Primary rhabdomyosarcoma (RMS) of the kidney in an adult is a very rare and unusual tumor in this site.
  • The differential diagnosis are mainly represented by sarcomatoid renal cell carcinoma.
  • According to the neoplastic extent, the treatment includes radical nephrectomy, chemotherapy and surgery.
  • The prognosis of primary renal RMS is extremely poor, with lymph node, hepatic, bone marrow and pulmonary metastasis and a short survival rate.
  • [MeSH-major] Kidney Neoplasms / pathology. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650305.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Kim DY, Kim KH, Jung SE, Lee SC, Park KW, Kim WK: Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg; 2002 Oct;37(10):1419-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy.
  • BACKGROUND/PURPOSE: Undifferentiated (embryonal) sarcoma of the liver (USL) is a rare malignancy found in older children, and the most appropriate treatment strategy has been controversial.
  • The authors report the tumor's clinical characteristics and the results of management in 6 children and recommend the best treatment plans based on these findings.
  • RESULTS: The mean age at diagnosis of USL was 10.3 years (range, 7 to 13 years).
  • Three children underwent primary complete resection without preoperative chemotherapy.
  • Partial resection of the tumor was done in one child because of encasing inferior vena cava and hepatic vein.
  • However, complete resection was possible at second-look operation after chemotherapy.
  • Two children underwent complete resection after chemotherapy.
  • Preoperative chemotherapy allowed successful resection of 3 USL, which were initially considered unresectable.
  • Chemotherapy according to the the Third Intergroup Rhabdomyosarcoma Study (IRS III) was administered to all except one child who refused further postoperative chemotherapy after having had severe complications during the first cycle of chemotherapy.
  • One child with partial resection died of sepsis at 22 months after diagnosis during postoperative chemotherapy after complete surgical removal of the tumor.
  • Five children are alive without recurrence at 40, 45, 48, 60, and 122 months, respectively, after diagnosis.
  • CONCLUSION: The combined therapy of surgery and chemotherapy in USL can improve the prognosis.
  • [MeSH-major] Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Mesenchymoma / drug therapy. Mesenchymoma / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Hepatectomy. Humans. Male. Prognosis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12378446.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sulis ML, Bessmertny O, Granowetter L, Weiner M, Kelly KM: Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol; 2004 Dec;26(12):843-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.
  • OBJECTIVES: Veno-occlusive disease (VOD) following standard chemotherapy has been reported in patients receiving vincristine actinomycin D, and cyclophosphamide for the treatment of Wilms tumor and more rarely rhabdomyosarcoma.
  • The dose and schedule of administration of actinomycin D in patients with Wilms tumor and the increased dose of cyclophosphamide administered to patients with rhabdomyosarcoma have been considered the likely etiology for VOD.
  • METHODS: The authors report four cases of VOD in patients with rhabdomyosarcoma treated with vincristine and actinomycin D only.
  • All patients recovered with no evidence of permanent hepatic damage.
  • CONCLUSIONS: VOD can occur in patients with "low-stage" rhabdomyosarcoma treated with vincristine and actinomycin D alone.
  • Although chemotherapy-related VOD is a potentially severe disease, the outcome is good and resumption of chemotherapy is well tolerated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatic Veno-Occlusive Disease / chemically induced. Rhabdomyosarcoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15591910.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


11. Yamaguchi K, Koga Y, Suminoe A, Saito Y, Matsuzaki A, Kanno S, Takimoto T, Suda M, Oda Y, Muto T, Takatsuki H, Hara T: [Alveolar rhabdomyosarcoma of unknown origin mimicking acute leukemia at the initial presentation]. Rinsho Ketsueki; 2007 Apr;48(4):315-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar rhabdomyosarcoma of unknown origin mimicking acute leukemia at the initial presentation].
  • Reverse transcriptase polymerase chain reaction demonstrated PAX3/FKHR fusion transcripts, confirming the diagnosis of alveolar rhabdomyosarcoma.
  • After three courses of chemotherapy containing etoposide, cyclophosphamide, pirarubicin, cisplatin and vincristine, tumor cells were eradicated from the bone marrow.
  • The patient received an allogeneic bone marrow transplantation eight months after diagnosis, although he died of hepatic veno-occlusive disease on day 21.
  • Alveolar rhabdomyosarcoma often develops in older children and younger adults, and its bone marrow infiltration may mimic acute leukemia.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Antigens, CD56 / analysis. Biomarkers, Tumor / analysis. Bone Marrow / pathology. Diagnosis, Differential. Disseminated Intravascular Coagulation / etiology. Fatal Outcome. Forkhead Transcription Factors / genetics. Humans. Leukemia. Male. Paired Box Transcription Factors / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515123.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  • [Number-of-references] 28
  •  go-up   go-down


12. Kobayashi N, Koizumi T, Eguchi T, Hyogotani A, Saito G, Hamanaka K, Shiina T, Kurai M, Kondo R, Yoshida K, Amano J: A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities. Anticancer Res; 2010 Dec;30(12):5117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities.
  • Rhabdomyosarcoma in the mediastinum coexisting with metastatic non-seminomatous germ cell tumor, so-called somatic-type malignancy, is a rare carcinoma and has poor survival.
  • This study reports a case of diffuse and huge hepatic metastasis of non-seminomatous germ cell tumor associated with coexisting embryonal rhabdomyosarcoma in the mediastinum.
  • A 31-year-old man presented with abdominal pain and was found to have multiple abnormal hepatic masses on abdominal computed tomography (CT).
  • Chemotherapy was initiated because the hepatic lesion was diagnosed as choriocarcinoma, based on histological findings and the elevation of chorionic gonadotropin β-subunit and α-fetoprotein.
  • After six cycles of bleomycin, etoposide and cisplatin chemotherapy the metastatic liver tumors showed complete response.
  • The histological findings revealed mature teratoma with embryonal rhabdomyosarcoma.
  • The patient has remained well for over six years after the treatment without any signs of disease recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Mediastinal Neoplasms / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Teratoma / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187499.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Rasmussen A, Kvist N, Kirkegaard P, Rechnitzer C: [Surgical treatment of children with hepatic tumours]. Ugeskr Laeger; 2008 Apr 14;170(16):1366-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of children with hepatic tumours].
  • [Transliterated title] Kirurgisk behandling af levertumorer hos børn.
  • INTRODUCTION: In this paper we review the results of surgical treatment of children with hepatic tumours.
  • MATERIALS AND METHODS: The study comprises 33 children who have undergone lever resection or liver transplantation since 1990.
  • 26 patients had hepatoblastoma, 3 had hepatocellular carcinoma, 2 had rhabdomyosarcoma, 1 had a mesenchymal tumour, and 1 had a giant haemangioma.
  • RESULTS: Because of the number of patients, we only analyzed the results of the treatment in the hepatoblastoma group.
  • The survival was the same after resection (77.3%) and liver transplantation (75%).
  • There was no difference in survival dependent on the type of resection, and there was no impact of the extension of tumour growth at the time of diagnosis.
  • CONCLUSION: The combination of neoadjuvant chemotherapy followed by liver resection or liver transplantation is the treatment of choice in all children with hepatoblastoma.
  • Since 2000, very effective chemotherapy has downstaged all referred patients, so subsequent liver resection have been possible.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Child. Hepatectomy. Humans. Liver Transplantation. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433603.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


14. Davidson A, Dick G, Pritchard-Jones K, Pinkerton R: EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. Eur J Cancer; 2002 Dec;38(18):2422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
  • Tumour types were neuroblastoma 3, Ewing's sarcoma 2, rhabdomyosarcoma 5, osteosarcoma 3, desmoplastic small round cell tumour 1, nephroblastoma 1, T-acute lymphoblastic leukaemia (ALL) 1.
  • All had progressed or relapsed following at least two of the drug types included in EVE.
  • Renal and hepatic toxicity was rarely severe and always transient.
  • Partial responses (PR) were observed in 2 patients (1 rhabdomyosarcoma, 1 Ewing's sarcoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclosporine / administration & dosage. Cyclosporine / adverse effects. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Heart Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Kidney Diseases / chemically induced. Male. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2002 Dec;38(18):2337-40 [12460776.001]
  • (PMID = 12460787.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


15. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation.
  • The objective of the present study was to describe our experience in liver resections, in the light of liver transplantation, emphasizing the indications for surgery, surgical techniques, complications, and results.
  • METHODS: The medical records of 53 children who underwent liver resection for primary or metastatic hepatic tumors were reviewed.
  • Ultrasonography, computed tomographic (CT) scan, and needle biopsy were the initial methods used to diagnose malignant tumors.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • Surgery was performed by surgeons competent in liver transplantation.
  • As in liver living donor operation, vascular anomalies were investigated.
  • The main arterial anomalies found were the right hepatic artery emerging from the superior mesenteric artery and left hepatic artery from left gastric artery.
  • Hilar structures were dissected very close to liver parenchyma.
  • The hepatic artery and portal vein were dissected and ligated near their entrance to the liver parenchyma to avoid damaging the hilar vessels of the other lobe.
  • During dissection of the suprahepatic veins, the venous infusion was decreased to reduce central venous pressure and potential bleeding from hepatic veins and the vena cava.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • Hepatic resections included 22 right lobectomies, 9 right trisegmentectomies, 8 left lobectomies, 5 left trisegmentectomies, 2 left segmentectomies, and 1 case of monosegment (segment IV) resection.
  • The overall mortality rate was 14.9%, and all deaths were related to recurrence of malignant disease.
  • The mortality rate of hepatoblastoma patients was less than other malignant tumors (P = .04).
  • CONCLUSION: The resection of hepatic tumors in children requires expertise in pediatric surgical practice, and many lessons learned from liver transplantation can be applied to hepatectomies.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944212.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Brumariu O, Miron I, Munteanu M, Enache G, Stan G, Mihailiuc C, Dimov V, Dumitrescu G, Rusu C, Mihăilă D: [Association between phakomatosis and neoplasia in children pathology. IV Pediatric Clinic experience]. Rev Med Chir Soc Med Nat Iasi; 2000 Apr-Jun;104(2):143-9
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk to developing a neoplasm is increased when associated to a patient phakomatosis (Recklinghausen neurofibromatosis, Bourneville's tuberous sclerosis).
  • The associated tumours were hematologic malignancies (juvenile myeloid chronic leukemia) and solid tumors (rhabdomyosarcoma, hepatic carcinoma, CNS tumour, NHL optic glioma).
  • The diagnosis was confirmed by microscopic examination of the bioptic material in all cases.
  • All cases had extensive and aggressive tumours at the moment of diagnosis, We noticed a poor response and an early relapse after chemotherapy.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Neurofibromatosis 1 / complications. Orbital Neoplasms / complications. Rhabdomyosarcoma / complications. Tuberous Sclerosis / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12089980.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 20
  •  go-up   go-down


17. Szumera M, Czauderna P, Popadiuk S, Gołebiewski J, Sznurkowska K, Renke J, Korzon M: [Assessment of treatment results in children with malignant liver tumours in own experience]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):539-49
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of treatment results in children with malignant liver tumours in own experience].
  • AIM: The assessment of malignant liver tumours in children treated in our centre between years 1985-2004 has been made in order to analyze the prognostic factors and improvement in survival rate.
  • MATERIAL AND METHODS: 17 patients with malignant liver tumours were followed-up.
  • There were 10 (58,8%) patients with hepatoblastomas, 5 (29,4%) hepatocarcinomas, 1 (5,9%) undifferentiated embryonal sarcoma and 1 (5,9%) rhabdomyosarcoma.
  • Primary metastatic disease was recognized in 3 cases as: hepatic vascular involvement, lungs, femoral bone and lymph nodes of liver hilus metastases.
  • All patients underwent preoperative chemotherapy.
  • Secondary metastases appeared in lungs, lymph nodes of liver hilus and central nervous system in 4 cases.
  • RESULTS: Twelve patients are alive with median follow-up 34,0 mths, five died with median survival time 16,0 mths.
  • Total excision of liver tumour had no statistical significance in lifetime prolongation (p =0,12).
  • CONCLUSIONS: Complete surgical excision had no statistical significance in increasing survival time in liver tumour patients.
  • Metastatic disease had statistical significance in shortening overall survival of patients with liver tumours.
  • Unsatisfactory results in hepatocarcinoma treatment in children dramatically demonstrate the need for new treatment approaches.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Hepatocellular. Child. Child, Preschool. Female. Follow-Up Studies. Hepatoblastoma / pathology. Hepatoblastoma / secondary. Hepatoblastoma / therapy. Humans. Infant. Male. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Oncology Service, Hospital / statistics & numerical data. Poland. Retrospective Studies. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719167.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Li EX, Zhang YT, Shang JT, Xu Z, Geng Y, Li SM, Shi F, Wu YY: [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma]. Ai Zheng; 2006 Aug;25(8):1048-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
  • BACKGROUND & OBJECTIVES: Clinical study suggests that 72-hour continuous infusion (CIV) of MAID regimen is more effective and achieves longer time of no progression than ADR-based two-drug regimen in advanced soft tissue sarcoma (ASTS) treatment, but has no improvement on the long-term survival.
  • Because of the severe grade 3/4 toxicities as well as treatment-related deaths, the regimen has not been widely applied in ASTS.
  • This study was to investigate the efficacy and toxicity of the modified MAID regimen in ASTS treatment.
  • All enrolled patients received chemotherapy (IFO 2,000 mg .
  • The therapy was repeated every 3 weeks for at least 2 cycles before evaluating the effects and toxicities.
  • Life table was used to calculate long-term survival rates and time to progression.
  • RESULTS: Fifty-four cases of evaluable patients had completed at least 2 cycles of modified MAID chemotherapy.
  • There were no other toxicities, such as hepatic and renal toxicities; no central nervous system toxicity and treatment-related deaths.
  • During 2 year follow-up, time to progression was 7 months, 1- and 2- year survival rates were 61.11% and 36.36%, respectively.
  • CONCLUSIONS: Modified MAID regimen simplifies the application of treatment procedure compared with original regimen, which three drugs have to be CIV simultaneously.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Synovial / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965692.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Kraemer DM, Waschke J, Kunzmann V, Wilhelm M: Veno-occlusive disease in a male patient with Marfan syndrome and common acute lymphoblastic leukemia during induction therapy. Ann Hematol; 2003 Jul;82(7):444-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Veno-occlusive disease in a male patient with Marfan syndrome and common acute lymphoblastic leukemia during induction therapy.
  • Veno-occlusive disease (VOD) of the liver is characterized by jaundice, painful hepatomegaly, and retention of fluids.
  • Additionally, the disease has been described in children suffering from nephroblastoma or rhabdomyosarcoma, treated with intense chemotherapy.
  • Recently, VOD has been shown to be a complication in the treatment of myeloid leukemia with anti-CD33 linked to calicheamicin.
  • We report the unusual case of a 21-year-old male patient with Marfan syndrome, diagnosed of acute lymphoblastic leukemia, who developed severe VOD during induction therapy after a single application of 2 mg vincristine.
  • We speculate that coincidence of Marfan syndrome and application of induction chemotherapy might favor the disease in our patient.
  • [MeSH-major] Hepatic Veno-Occlusive Disease / etiology. Marfan Syndrome / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Male. Remission Induction. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Marfan syndrome.
  • MedlinePlus Health Information. consumer health - Marfan Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12761649.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine
  •  go-up   go-down


20. Oue T, Kubota A, Okuyama H, Kawahara H, Inoue M, Yagi K, Kawa K: Megatherapy with hematopoietic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies. J Pediatr Surg; 2003 Jan;38(1):130-3; discussion 130-3
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megatherapy with hematopoietic stem cell rescue as a preoperative treatment in unresectable pediatric malignancies.
  • BACKGROUND/PURPOSE: To improve the quality of life and prognosis of the patients with advanced pediatric malignant tumors, the authors have used megatherapy (MT) with hematopoietic stem cell transplantation (SCT) before surgery.
  • To elucidate the impact of preoperative MT on the treatments of pediatric advanced malignancies, the authors reviewed the timing of surgery, preoperative condition, postoperative recovery, and outcome.
  • METHODS: Between 1991 and 2001, 24 children with malignant tumors received MT with SCT before surgery, and 19 tumors were resected after SCT.
  • These tumors included 12 neuroblastomas, 2 hepatic tumors, 2 peripheral primitive neuroectodermal tumors, one rhabdomyosarcoma, one Wilms' tumor, and one yolk sac tumor.
  • At 7 months to 7 years after diagnosis, 9 patients are alive without disease, one with disease, 6 have died of recurrent tumor, and 2 have died of chemotherapy-associated complications.
  • In the treatment of advanced pediatric malignancies, especially in the case of unresectable tumor, preoperative MT with SCT should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Neoplasms / drug therapy. Neoplasms / therapy. Preoperative Care / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12592635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK: Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol; 2000 Nov;35(5):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that much higher dosing would meet critical goals of salvage therapy: antitumor effect and a lack of toxicity to key organs, so as not to preclude subsequent consolidative treatments needed for cure.
  • PROCEDURE: Patients with resistant pediatric solid tumors received cyclophosphamide 4,200 mg/m(2) by 48 hr infusion, and topotecan 6 mg/m(2) by 72 hr infusion (HD-Cy/Topo).
  • All patients had previously received > or =6 cycles of other therapy, high-dose alkylator-based chemotherapy, and/or etoposide- and doxorubicin-containing regimens.
  • After HD-Cy/Topo, cardiac, renal, hepatic, and pulmonary function remained within the normal range.
  • Partial or minor responses were noted in neuroblastoma, desmoplastic small round-cell tumor, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.
  • It may also merit incorporation into frontline treatment protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Female. Humans. Male. Neuroblastoma / drug therapy. Pilot Projects. Sarcoma / drug therapy. Topotecan / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11070479.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


22. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Diagnostic investigation presented a cerebral, pulmonary, cutaneous, hepatic and pleural metastatic disease.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy
  • [MeSH-minor] Aged. Axilla. Fatal Outcome. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J, Pearson AD, Boddy AV, UKCCSG Pharmacology Working Group: Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct 5;795(2):237-43
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry.
  • Actinomycin D is an anti-cancer drug commonly used in the treatment of paediatric malignancies such as Wilms' tumour, Ewing's sarcoma and rhabdomyosarcoma.
  • As actinomycin D treatment in children with cancer is associated with veno-occlusive disease (VOD), and as the dose intensity of actinomycin D treatment has been defined as a significant risk factor for the development of this potentially life-threatening hepatic toxicity, pharmacokinetic studies of actinomycin D may be beneficial in optimizing treatment with this drug.
  • In order to investigate this issue, we developed a sensitive liquid chromatography-mass spectrometry (LC-MS) method for the determination of actinomycin D in human plasma samples.
  • A limit of quantitation of 1.0 ng/ml was determined, allowing the reliable measurement of actinomycin D in plasma samples obtained from patients receiving this drug clinically.
  • [MeSH-minor] Child. Humans. Neoplasms / drug therapy. Reference Standards

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522028.001).
  • [ISSN] 1570-0232
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


24. Hingorani P, Zhang W, Piperdi S, Pressman L, Lin J, Gorlick R, Kolb EA: Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol; 2009 Sep;64(4):733-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Oxazaphosphorines, such as ifosfamide (IFA), are frequently used in the treatment of pediatric sarcomas.
  • They are pro-drugs and undergo hepatic metabolism into the active moiety and potentially toxic by-products such as acrolein and chloracetaldehyde, which may cause hemorrhagic cystitis and encephalopathy, respectively.
  • METHODS: The cytotoxic effect of palifosfamide lysine was studied in osteosarcoma (OS), Ewing's sarcoma (ES) and rhabdomyosarcoma (RMS) cell lines using the MTT assay.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ifosfamide / analogs & derivatives. Lysine / analogs & derivatives. Osteosarcoma / drug therapy
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. DNA Primers. Drug Resistance, Neoplasm. Female. Gene Expression. Humans. Mice. Mice, SCID. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224214.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / palifosfamide lysine; K3Z4F929H6 / Lysine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement